BMI1-Mediated Pemetrexed Resistance in Non-Small Cell Lung Cancer Cells Is Associated with Increased SP1 Activation and Cancer Stemness

Lung cancer is the leading cause of cancer death worldwide and the therapeutic strategies include surgery, chemotherapy and radiation therapy. Non-small cell lung cancers (NSCLCs) account for around 85% of cases of lung cancers. Pemetrexed is an antifolate agent that is currently used as the second...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Huan-Ting, Chien, Peng-Ju, Chen, Shih-Hong, Sheu, Gwo-Tarng, Jan, Ming-Shiou, Wang, Bing-Yen, Chang, Wen-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463866/
https://www.ncbi.nlm.nih.gov/pubmed/32726929
http://dx.doi.org/10.3390/cancers12082069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463866/
https://www.ncbi.nlm.nih.gov/pubmed/32726929
http://dx.doi.org/10.3390/cancers12082069

Ejemplares similares